ArticleEndocrine-related cancer2016
EMT reversal in human cancer cells after IR knockdown in hyperinsulinemic mice.
Article in Endocrine-related cancer, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
22 citing papers in PubMed, 31 citations in OpenAlex.
- Insulin receptor expression and its association with hyperinsulinemia in triple negative breast cancer.Journal of the Endocrine Society · 2026Article
- Correlation between insulin receptor expression and tumor cell proliferation, recurrence and metastasis in well-differentiated pancreatic neuroendocrine neoplasms.Endocrine connections · 2025Article
- Article
- Breast cancer shares many epidemiological, lifestyle, and local hormonal and metabolic underpinnings with endometrial and ovarian cancer: a narrative review.Translational breast cancer research : a journal focusing on translational research in breast cancer · 2025Review
- Prevalence and impact of diabetes on survival of patients with multiple myeloma in different racial groups.Blood advances · 2024Article
- Integrative bioinformatics analysis of biomarkers and pathways for exploring the mechanisms and molecular targets associated with pyroptosis in type 2 diabetes mellitus.Frontiers in endocrinology · 2023Article
- Network Pharmacology Study to Reveal the Potentiality of a Methanol Extract ofLife (Basel, Switzerland) · 2022Article
- The Intricate Crosstalk Between Insulin and Pancreatic Ductal Adenocarcinoma: A Review From Clinical to Molecular.Frontiers in cell and developmental biology · 2022Review
- TMEM176B Regulates AKT/mTOR Signaling and Tumor Growth in Triple-Negative Breast Cancer.Cells · 2021Article
- Article
- The Emerging Role of the Fetal Insulin Receptor in Hormone-refractory Breast Cancer.Endocrinology · 2021Review
- Hyperinsulinaemia in cancer.Nature reviews. Cancer · 2020Review
- Obesity, Type 2 Diabetes, and Cancer Risk.Frontiers in oncology · 2020Review
- Microenvironmental Determinants of Breast Cancer Metastasis: Focus on the Crucial Interplay Between Estrogen and Insulin/Insulin-Like Growth Factor Signaling.Frontiers in cell and developmental biology · 2020Review
- Identification of two microRNA nodes as potential cooperative modulators of liver metabolism.Hepatology research : the official journal of the Japan Society of Hepatology · 2019Article
- Hyperinsulinemia promotes aberrant histone acetylation in triple-negative breast cancer.Epigenetics & chromatin · 2019Article
- Insulin Receptor Isoforms in Cancer.International journal of molecular sciences · 2018Review
- Diabetes, Obesity, and Breast Cancer.Endocrinology · 2018Review
- Insulin Receptor Isoforms in Physiology and Disease: An Updated View.Endocrine reviews · 2017Review
- OP449 inhibits breast cancer growth without adverse metabolic effects.Endocrine-related cancer · 2017Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 3 institutions in 1 country.
Funding
Abstract
Type 2 diabetes (T2D) is associated with increased cancer risk and cancer-related mortality. Data herein show that we generated an immunodeficient hyperinsulinemic mouse by crossing the Rag1(-/-) mice, which have no mature B or T lymphocytes, with the MKR mouse model of T2D to generate the Rag1(-/-) (Rag/WT) and Rag1(-/-)/MKR(+/+) (Rag/MKR) mice. The female Rag/MKR mice are insulin resistant and have significantly higher nonfasting plasma insulin levels compared with the Rag/WT controls. Therefore, we used these Rag/MKR mice to investigate the role of endogenous hyperinsulinemia on human cancer progression. In this study, we show that hyperinsulinemia in the Rag/MKR mice increases the expression of mesenchymal transcription factors, TWIST1 and ZEB1, and increases the expression of the angiogenesis marker, vascular endothelial growth factor A (VEGFA). We also show that silencing the insulin receptor (IR) in the human LCC6 cancer cells leads to decreased tumor growth and metastases, suppression of mesenchymal markers vimentin, SLUG, TWIST1 and ZEB1, suppression of angiogenesis markers, VEGFA and VEGFD, and re-expression of the epithelial marker, E-cadherin. The data in this paper demonstrate that IR knockdown in primary tumors partially reverses the growth-promoting effects of hyperinsulinemia as well as highlighting the importance of the insulin receptor signaling pathway in cancer progression, and more specifically in epithelial-mesenchymal transition.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.